Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of oral KVD900 for on-demand treatment of hereditary angioedema attacks
MOH_2022-09-29_012079Phase 3Active, not recruiting
- Sponsor
- KalVista Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by KalVista Pharmaceuticals. Primary endpoint: Long-term safety. Started Aug 2022; status: active, not recruiting.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on MOH_2022-09-29_012079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-29_012079.